国产日韩午夜视频在线观看,狼友在线视频,色妞www精品视频,a天堂视频在线观看,熟女精品激情免费视频,午夜福利二区无码在线,午夜夜伦鲁鲁片免费无码,99成人福利免费视频
      歡迎來(lái)到范德生物BIOFOUNT
      范德生物中國(guó)
      范德生物產(chǎn)品購(gòu)買購(gòu)物車
      0
      搜索
      864677-55-4
      • names:

        IT1t

      • CAS號(hào):

        864677-55-4

        MDL Number: No data available
      • MF(分子式): C21H34N4S2 MW(分子量): 406.65
      • EINECS:No data available Reaxys Number:No data available
      • Pubchem ID:25147749 Brand:BIOFOUNT
      IT1t
      IT1t(864677-55-4)是一種選擇性的CXCR4拮抗劑,在鈣動(dòng)員試驗(yàn)中IC50值為1.1 nM,可能作為抗HIV藥物有用。
      貨品編碼 規(guī)格 純度 價(jià)格 (¥) 現(xiàn)價(jià)(¥) 特價(jià)(¥) 庫(kù)存描述 數(shù)量 總計(jì) (¥)
      YZM000668-10mg 10mg ¥ 1518.00 ¥ 1518.00 Backorder
      - +
      0.00
      YZM000668-5mg 5mg >97% ¥ 828.75 ¥ 828.75 2-3天
      - +
      0.00
      快速詢價(jià)
      收起
      你想詢價(jià)的產(chǎn)品
      請(qǐng)準(zhǔn)確填寫您的聯(lián)系方式,以便為您提供最好的服務(wù)。
      中文別名 IT1t(864677-55-4); N,N′-二環(huán)己基氨基甲硫基硫酸(5,6-二氫-6,6-二甲基咪唑并[2,1-b]噻唑-3-基)甲基酯; 1092776-63-0(HCl鹽); N,N′-二環(huán)己基氨基甲硫氨酸(5,6-二氫-6,6-二甲基咪唑并[2,1-b]噻唑-3-基)甲基酯;
      英文別名 IT1t(864677-55-4); N,N'-Dicyclohexylcarbamimidothioic Acid (5,6-Dihydro-6,6-dimethylimidazo[2,1-b]thiazol-3-yl)methyl Ester;1092776-63-0 (HCl salt);
      CAS號(hào) 864677-55-4
      Inchi InChI=1S/C21H34N4S2/c1-21(2)15-25-18(14-27-20(25)24-21)13-26-19(22-16-9-5-3-6-10-16)23-17-11-7-4-8-12-17/h14,16-17H,3-13,15H2,1-2H3,(H,22,23)
      InchiKey OOSUDWRRWZVFEB-UHFFFAOYSA-N
      分子式 Formula C21H34N4S2
      分子量 Molecular Weight 406.65
      溶解度Solubility
      性狀 Solid
      儲(chǔ)藏條件 Storage conditions -20℃冰柜請(qǐng)根據(jù)產(chǎn)品建議的存儲(chǔ)條件進(jìn)行存儲(chǔ),Please store the product under the recommended condition sin the description.

      IT1t(864677-55-4)實(shí)驗(yàn)注意事項(xiàng):
      1.實(shí)驗(yàn)前需戴好防護(hù)眼鏡,穿戴防護(hù)服和口罩,佩戴手套,避免與皮膚接觸。
      2.實(shí)驗(yàn)過程中如遇到有毒或者刺激性物質(zhì)及有害物質(zhì)產(chǎn)生,必要時(shí)實(shí)驗(yàn)操作需要手套箱內(nèi)完成以免對(duì)實(shí)驗(yàn)人員造成傷害
      3.實(shí)驗(yàn)后產(chǎn)生的廢棄物需分類存儲(chǔ),并交于專業(yè)生物廢氣物處理公司處理,以免造成環(huán)境污染Experimental considerations:
      1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
      2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.
      Tags:IT1t試劑,IT1t雜質(zhì),IT1t中間體,IT1t密度,IT1t溶解度,IT1t旋光度,IT1t閃點(diǎn),IT1t購(gòu)買,IT1t熔點(diǎn),
      產(chǎn)品說(shuō)明 (864677-55-4)IT1t是高效的CXCR4拮抗劑;抑制CXCL12/CXCR4相互作用的IC50值是2.1 nM
      Introduction(864677-55-4)IT1t is a potentCXCR4antagonist; inhibits CXCL12/CXCR4 interaction with anIC50of 2.1 nM.
      Application1IT1t(864677-55-4)是抗艾滋病毒劑。
      Application2
      Application3

      IT1t(864677-55-4)藥理學(xué):


      IT1t是一種選擇性的CXCR4拮抗劑,在鈣動(dòng)員試驗(yàn)中IC50值為1.1 nM,可能作為抗HIV藥物有用。


      Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4 PMID 24923360; Chemical biology & drug design 2015 Feb; 85(2):119-36 Name matches
      Anti-HIV small-molecule binding in the peptide subpocket of the CXCR4:CVX15 crystal structure PMID 24990206; Chembiochem : a European journal of chemical biology 2014 Jul; 15(11):1614-20 Name matches:
      Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors PMID 28410420; PloS one 2017; 12(4):e0176057 Name matches: amd11070 it1t
      Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors PMID 28410420; PloS one 2017; 12(4):e0176057 Name matches: amd3465 it1t
      Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4 PMID 24923360; Chemical biology & drug design 2015 Feb; 85(2):119-36 Name matches
       
      IT1t(864677-55-4)參考文獻(xiàn):
      1.Insights into the mechanism of inhibition of CXCR4: identification of Piperidinylethanamine analogs as anti-HIV-1 inhibitors.
      Das D;Maeda K;Hayashi Y;Gavande N;Desai DV;Chang SB;Ghosh AK;Mitsuya H Antimicrob Agents Chemother. 2015 Apr;59(4):1895-904. doi: 10.1128/AAC.04654-14. Epub 2015 Jan 12.

      The cellular entry of HIV-1 into CD4(+) T cells requires ordered interactions of HIV-1 envelope glycoprotein with C-X-C chemokine receptor type 4 (CXCR4) receptors. However, such interactions, which should be critical for rational structure-based discovery of new CXCR4 inhibitors, remain poorly understood. Here we first determined the effects of amino acid substitutions in CXCR4 on HIV-1NL 4 - 3 glycoprotein-elicited fusion events using site-directed mutagenesis-based fusion assays and identified 11 potentially key amino acid substitutions, including D97A and E288A, which caused >30% reductions in fusion. We subsequently carried out a computational search of a screening library containing ∼604,000 compounds, in order to identify potential CXCR4 inhibitors. The computational search used the shape of IT1t, a known CXCR4 inhibitor, as a reference and employed various algorithms, including shape similarity, isomer generation, and docking against a CXCR4 crystal structure. Sixteen small molecules were identified for biological assays based on their high shape similarity to IT1t, and their putative binding modes formed hydrogen bond interactions with the amino acids identified above. Three compounds with piperidinylethanamine cores showed activity and were resynthesized.

      2.Hologram quantitative structure activity relationship, docking, and molecular dynamics studies of inhibitors for CXCR4.
      Zhang C;Du C;Feng Z;Zhu J;Li Y Chem Biol Drug Des. 2015 Feb;85(2):119-36. doi: 10.1111/cbdd.12377. Epub 2014 Jul 10.

      CXCR4 plays a crucial role as a co-receptor with CCR5 for HIV-1 anchoring to mammalian cell membrane and is implicated in cancer metastasis and inflammation. In the current work, we study the relationship of structure and activity of AMD11070 derivatives and other inhibitors of CXCR4 using HQSAR, docking and molecular dynamics (MD) simulations. We obtain an HQSAR model (q(2) = 0.779), and the HQSAR result illustrates that AMD11070 shows a high antiretroviral activity. As HQSAR only provides 2D information, we perform docking and MD to study the interaction of It1t, AMD3100, and AMD3465 with CXCR4. Our results illustrate that the binding are affected by two crucial residues Asp97 and Glu288. The butyl amine moiety of AMD11070 contributes to its high antiretroviral activity. Without a butyl amine moiety, (2,7a-Dihydro-1H-benzoimidazol-2-ylmethyl)-methyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine (compound 5a) shows low antiretroviral activity. Our results provide structural details about the interactions between the inhibitors and CXCR4, which are useful for rational drug design of CXCR4.

      3.Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.
      Van Hout A;D'huys T;Oeyen M;Schols D;Van Loy T PLoS One. 2017 Apr 14;12(4):e0176057. doi: 10.1371/journal.pone.0176057. eCollection 2017.

      The chemokine receptor CXCR4 is activated by its unique chemokine ligand CXCL12 and regulates many physiological and developmental processes such as hematopoietic cell trafficking. CXCR4 is also one of the main co-receptors for human immunodeficiency virus (HIV) entry. Dysfunction of the CXCL12/CXCR4 axis contributes to several human pathologies, including cancer and inflammatory diseases. Consequently, inhibition of CXCR4 activation is recognized as an attractive target for therapeutic intervention. In this regard, numerous agents modifying CXCR4 activity have been evaluated in in vitro experimental studies and pre-clinical models. Here, we evaluated a CXCL12 competition binding assay for its potential as a valuable initial screen for functional and competitive CXCR4 inhibitors. In total, 11 structurally diverse compounds were included in a side-by-side comparison of in vitro CXCR4 cell-based assays, such as CXCL12 competition binding, CXCL12-induced calcium signaling, CXCR4 internalization, CXCL12-guided cell migration and CXCR4-specific HIV-1 replication experiments. Our data indicated that agents that inhibit CXCL12 binding, i.e. the anti-CXCR4 peptide analogs T22, T140 and TC14012 and the small molecule antagonists AMD3100, AMD3465, AMD11070 and IT1t showed inhibitory activity with consistent relative potencies in all further applied CXCR4-related assays.

        對(duì)不起,暫無(wú)產(chǎn)品評(píng)價(jià)!
      MSDS
      SDS 1.0 中文
      展開
      SDS 1.0 英文
      展開
            新聞

            怎么做細(xì)胞爬片免疫組化染色實(shí)驗(yàn)

            細(xì)胞爬片免疫組化染色,是通過細(xì)胞爬片是讓玻片浸在細(xì)胞培養(yǎng)基內(nèi),細(xì)胞在玻片上生長(zhǎng),主要用于組織學(xué),免疫組織化學(xué)...

            2020/7/20 22:04:33

            提取病毒RNA的實(shí)驗(yàn)方法

            提取病毒RNA方法分別有:異硫氰酸胍的提取病毒RNA方法、TRIzol LS提取法、Trizol法提取法等等...

            2020/7/22 20:29:26

            chelex 100樹脂國(guó)產(chǎn)替代之路-BIOFOUNT范德生物

            Chelex 100螯合離子交換樹脂對(duì)銅、鐵和其他重金屬?的偏好顯著高于對(duì)鈉、鉀等一價(jià)陽(yáng)離子的偏好。它對(duì)二價(jià)...

            2025/11/4 14:22:46

            9月開學(xué)季——助研新學(xué)期 范德送好禮

            2025/8/28 15:30:55

            Waxfilm 實(shí)驗(yàn)室封口膜:技術(shù)與國(guó)際市場(chǎng)的雙重突破

            在實(shí)驗(yàn)室耗材領(lǐng)域,封口膜是保障實(shí)驗(yàn)準(zhǔn)確性與穩(wěn)定性的關(guān)鍵產(chǎn)品之一。近年來(lái),Waxfilm?實(shí)驗(yàn)室封口膜憑借其卓...

            2025/5/13 13:03:40

            Waxfilm實(shí)驗(yàn)室封口膜的5大突破

            Waxfilm實(shí)驗(yàn)室封口膜作為生物功能膜領(lǐng)域的國(guó)產(chǎn)技術(shù)突破和品牌突破,是生物領(lǐng)域中國(guó)技術(shù)發(fā)展的縮影。

            2025/5/6 17:02:07

            各種微流控芯片鍵合方法的優(yōu)缺點(diǎn)

            微流控芯片鍵合:目前主要有激光焊接、熱壓鍵合、膠鍵合、超音波焊接,每種方法都有各自的優(yōu)缺點(diǎn)。本文主要介紹聚酯...

            2023/7/28 10:43:09

            新一代微流控鍵合解決方案

            微流控鍵合解決方案:微流控芯片制造的一個(gè)重要環(huán)節(jié),也是最容易被忽視的--芯片鍵合。其中一個(gè)重要因素是:微流控...

            2023/7/27 12:44:28

            熒光素鉀鹽使用說(shuō)明

            D-熒光素鉀鹽(K+)設(shè)計(jì)用于體外和體內(nèi)生物發(fā)光測(cè)定。D-熒光素的質(zhì)量和純度對(duì)于獲得良好和可重復(fù)的結(jié)果至關(guān)重...

            2023/7/20 11:05:11

            如何選BSA(牛血清白蛋白)

            如何選BSA(牛血清白蛋白):牛血清白蛋白(BSA)有多種形式,如何選擇適合自己的牛血清白蛋白(BSA)是一...

            2023/2/14 13:09:18

            My title page contents